BIOMAT Database Logo BIOMAT Database Logo

[Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin]. 1990

C J Soussy, and J Le Van Thoi, and J Duval
Service de Bactériologie, CHU Henri-Mondor, Créteil.

In vitro antibacterial activity of 5 quinolones: nalidixic acid (NAL), pefloxacin (PEF), norfloxacin (NOR), ofloxacin (OFL) and ciprofloxacin (CIP) was evaluated by agar diffusion (disks Diagnostics Pasteur) for 1,253 bacterial strains (767 Enterobacteriaceae: E 164 P. aeruginosa: PA, 90 A. baumannii: AB and 232 S. aureus: SA) isolated during the last three months of 1988. Strains were ranged in susceptible (S) intermediate (I) and resistant (R) according to recommendations of Comité Français de l'Antibiogramme; in addition, activity of NOR, OFL and CIP was precised according to susceptibility to NAL and PEF. Frequencies of strains R + I observed for NAL, PEF, NOR, OFL and CIP were (%): E: 14.4; 13.4; 7.3; 7.6; 2.4 - PA: 100; 68.5; 18.4; 36.8; 8.9 - AB: 78.9; 57.8; 75.5; 54.4; 50 - SA: 100; 27.5; 28.9; 28.5; 28.7. For E and AB, analysis according to resistance phenotypes to NAL and PEF showed reduction of activity of NOR, OFL and CIP, on strains RI and particularly RR by comparison with strains SS and RS. Activity of PEF, NOR, OFL and CIP is similar on PA, belonging to RS and RR phenotypes. On RI strains, only CIP showed activity practically identical to that on RS strains. For SA, NOR, OFL and CIP were inactive on PEF R strains. Analysis of populations of strains according to resistance phenotypes to NAL and PEF permitted to show reduction of activity of other compounds on strains with an acquired resistance character to quinolones; currently, only test of PEF is presently sufficient for susceptibility testing of other fluoroquinolones (NOR, OFL and CIP) on E, AB and SA; however for PA, test of CIP is also necessary.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006088 Gram-Negative Aerobic Bacteria A large group of aerobic bacteria which show up as pink (negative) when treated by the gram-staining method. This is because the cell walls of gram-negative bacteria are low in peptidoglycan and thus have low affinity for violet stain and high affinity for the pink dye safranine. Achromatiaceae,Achromatium,Achromobacteriaceae,Gram Negative Aerobic Bacteria
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D015242 Ofloxacin A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. DL-8280,DR-3355,Hoe-280,ORF-28489,Ofloxacin Hydrochloride,Ofloxacine,Ru-43280,Tarivid,DL 8280,DL8280,DR 3355,DR3355,Hoe 280,Hoe280,ORF 28489,ORF28489,Ru 43280,Ru43280
D015366 Pefloxacin A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. 2589 R.B.,Abactal,Peflacine,Pefloxacin Mesylate,Pefloxacin Mesylate Dihydrate,Pefloxacine,Silver Pefloxacin,Dihydrate, Pefloxacin Mesylate,Mesylate Dihydrate, Pefloxacin,Mesylate, Pefloxacin,Pefloxacin, Silver,R.B., 2589

Related Publications

C J Soussy, and J Le Van Thoi, and J Duval
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
May 1984, Antimicrobial agents and chemotherapy,
C J Soussy, and J Le Van Thoi, and J Duval
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
April 1983, European journal of clinical microbiology,
C J Soussy, and J Le Van Thoi, and J Duval
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
September 1984, The Journal of antimicrobial chemotherapy,
C J Soussy, and J Le Van Thoi, and J Duval
[Serum pharmacokinetics and in vitro antibacterial activity of pefloxacin, ofloxacin and ciprofloxacin].
January 1990, Presse medicale (Paris, France : 1983),
C J Soussy, and J Le Van Thoi, and J Duval
[Comparative activities in vitro of 4 quinolones (nalidixic acid, pefloxacin, norfloxacin, ofloxacin) on 13 bacterial species].
January 1992, Archives de l'Institut Pasteur d'Algerie. Institut Pasteur d'Algerie,
C J Soussy, and J Le Van Thoi, and J Duval
[Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
June 1985, Pathologie-biologie,
C J Soussy, and J Le Van Thoi, and J Duval
[The antibacterial effect of ciprofloxacin, ofloxacin and norfloxacin in vitro].
November 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,
C J Soussy, and J Le Van Thoi, and J Duval
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
August 1988, Antimicrobial agents and chemotherapy,
C J Soussy, and J Le Van Thoi, and J Duval
Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
January 1985, Drugs under experimental and clinical research,
C J Soussy, and J Le Van Thoi, and J Duval
Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.
February 1986, Pharmaceutisch weekblad. Scientific edition,
Copied contents to your clipboard!